Zacks Research Has Bearish Estimate for LLY Q1 Earnings

Eli Lilly and Company (NYSE:LLY - Free Report) - Analysts at Zacks Research dropped their Q1 2026 earnings estimates for shares of Eli Lilly and Company in a report issued on Tuesday, April 22nd. Zacks Research analyst K. Shah now expects that the company will post earnings per share of $6.27 for the quarter, down from their previous forecast of $6.30. The consensus estimate for Eli Lilly and Company's current full-year earnings is $23.48 per share. Zacks Research also issued estimates for Eli Lilly and Company's Q2 2026 earnings at $7.29 EPS, Q3 2026 earnings at $8.20 EPS, Q4 2026 earnings at $9.39 EPS and FY2026 earnings at $31.15 EPS.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%.

Several other equities research analysts have also recently weighed in on LLY. Leerink Partners set a $950.00 price objective on shares of Eli Lilly and Company in a research report on Friday, January 17th. StockNews.com raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Guggenheim cut their target price on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Wells Fargo & Company boosted their target price on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Finally, Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $1,000.32.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded up $14.21 during mid-day trading on Friday, hitting $891.50. 1,241,051 shares of the stock were exchanged, compared to its average volume of 3,436,220. The stock's fifty day simple moving average is $827.90 and its two-hundred day simple moving average is $816.88. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The company has a market cap of $845.30 billion, a P/E ratio of 76.13, a PEG ratio of 1.40 and a beta of 0.51.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.13% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Sharp Financial Services LLC boosted its position in Eli Lilly and Company by 16.9% during the first quarter. Sharp Financial Services LLC now owns 381 shares of the company's stock worth $315,000 after purchasing an additional 55 shares during the period. Novare Capital Management LLC raised its holdings in Eli Lilly and Company by 218.4% in the 1st quarter. Novare Capital Management LLC now owns 1,869 shares of the company's stock valued at $1,544,000 after acquiring an additional 1,282 shares during the period. Adell Harriman & Carpenter Inc. boosted its holdings in shares of Eli Lilly and Company by 13.2% during the first quarter. Adell Harriman & Carpenter Inc. now owns 14,336 shares of the company's stock worth $11,841,000 after acquiring an additional 1,669 shares during the period. Concurrent Investment Advisors LLC grew its position in shares of Eli Lilly and Company by 12.9% in the first quarter. Concurrent Investment Advisors LLC now owns 27,675 shares of the company's stock valued at $22,857,000 after purchasing an additional 3,155 shares during the last quarter. Finally, World Investment Advisors increased its stake in shares of Eli Lilly and Company by 7.1% during the first quarter. World Investment Advisors now owns 17,756 shares of the company's stock worth $14,664,000 after purchasing an additional 1,182 shares during the period. 82.53% of the stock is currently owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.